MedAlliance announced today that it enrolled the first patient in an erectile dysfunction (ED) feasibility study with its drug-eluting balloon (DEB).
Nyon, Switzerland-based MedAlliance’s first patient was enrolled in the trial at the University of Rome Tor Vergata, Italy, under the direction of principal investigator Giuseppe Sangiorgi, a professor of cardiovascular interventional pathology.
Get the full story at our sister site, Drug Delivery Business News.